Evidence map›Paper›PMID 26588902›Full record

ArticleBMC public health2015

Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa.

Ayesha B M Kharsany, Cherie Cawood, David Khanyile, Anneke Grobler, Lyle R Mckinnon, Natasha Samsunder, Janet A Frohlich, Quarraisha Abdool Karim, Adrian Puren, Alex Welte and 9 more

Abstract read
In one paragraph

Article in BMC public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ayesha B M KharsanyCentre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, 2nd Floor, Private Bag 7, Congella, 4013, Durban, South Africa. Ayesha.Kharsany@caprisa.org.
Cherie CawoodEpicentre AIDs Risk Management (Pty) Limited, P O Box 3484, Paarl, 7620, Cape Town, South Africa. Cheriec@epicentre.org.za.
David KhanyileEpicentre AIDs Risk Management (Pty) Limited, P O Box 3484, Paarl, 7620, Cape Town, South Africa. Davidk@epicentre.org.za.
Anneke GroblerCentre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, 2nd Floor, Private Bag 7, Congella, 4013, Durban, South Africa. Anneke.Grobler@caprisa.org.
Lyle R MckinnonCentre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, 2nd Floor, Private Bag 7, Congella, 4013, Durban, South Africa. Lyle.Mckinnon@caprisa.org.
Natasha SamsunderCentre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, 2nd Floor, Private Bag 7, Congella, 4013, Durban, South Africa. Natasha.Samsunder@caprisa.org.
Janet A FrohlichCentre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, 2nd Floor, Private Bag 7, Congella, 4013, Durban, South Africa. Janet.Frohlich@caprisa.org.
Quarraisha Abdool KarimCentre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, 2nd Floor, Private Bag 7, Congella, 4013, Durban, South Africa. Quarraisha.AbdoolKarim@caprisa.org.
Adrian PurenCentre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service (NICD/NHLS), Johannesburg, South Africa. adrianp@nicd.ac.za.
Alex WelteSouth African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch, South Africa. alexwelte@sun.ac.za.
Gavin GeorgeHealth Economics and HIV and AIDS Research Division (HEARD), University of KwaZulu-Natal, KwaZulu-Natal, South Africa. Georgeg@ukzn.ac.za.
Kaymarlin GovenderHealth Economics and HIV and AIDS Research Division (HEARD), University of KwaZulu-Natal, KwaZulu-Natal, South Africa. Govenderk2@ukzn.ac.za.
Carlos ToledoCentres for Disease Control and Prevention (CDC) Atlanta, Atlanta, USA. cot8@cdc.gov.
Zawadi ChipetaCentres for Disease Control and Prevention (CDC), Pretoria, South Africa. chipetaz@sa.cdc.gov.
Lycias ZembeCentres for Disease Control and Prevention (CDC), Pretoria, South Africa. xxc4@cdc.gov.
Mary T GlenshawCentres for Disease Control and Prevention (CDC), Pretoria, South Africa. fev5@cdc.gov.
Lorna MaduraiGlobal Clinical and Virology Laboratory, 11 Dan Pienaar Place, Amanzimtoti, South Africa. MLorna@GCVLABS.CO.ZA.
Varough M DeydeCentres for Disease Control and Prevention (CDC), Pretoria, South Africa. che5@cdc.gov.
Alfred BereCentres for Disease Control and Prevention (CDC), Pretoria, South Africa. yek8@cdc.gov.

Funding

CGH CDC HHS U2G GH000372PEPFARPHS HHS 3U2GGH000372-02
6 · The paper itself

Abstract

backgroundSouth Africa has over 6,000,000 HIV infected individuals and the province of KwaZulu-Natal (KZN) is the most severely affected. As public health initiatives to better control the HIV epidemic are implemented, timely, detailed and robust surveillance data are needed to monitor, evaluate and inform the programmatic interventions and policies over time. We describe the rationale and design of the HIV Incidence Provincial Surveillance System (HIPSS) to monitor HIV prevalence and incidence. METHODS/

designThe household-based survey will include a sample of men and women from two sub-districts of the uMgungundlovu municipality (Vulindlela and the Greater Edendale) of KZN, South Africa. The study is designed as two sequential cross-sectional surveys of 10,000 randomly selected individuals aged 15-49 years to be conducted one year apart. From the cross sectional surveys, two sequential cohorts of HIV negative individuals aged 15-35 years will be followed-up one year later to measure the primary outcome of HIV incidence. Secondary outcomes include the laboratory measurements for pulmonary tuberculosis, sexually transmitted infections and evaluating tests for estimating population-level HIV incidence. Antiretroviral therapy (ART) access, HIV-1 RNA viral load, and CD4 cell counts in HIV positive individuals will assess the effectiveness of the HIV treatment cascade. Household and individual-level socio-demographic characteristics, exposure to HIV programmatic interventions and risk behaviours will be assessed as predictors of HIV incidence. The incidence rate ratio of the two cohorts will be calculated to quantify the change in HIV incidence between consecutive samples. In anticipation of better availability of population-level HIV prevention and treatment programmes leading to decreases in HIV incidence, the sample size provides 84% power to detect a reduction of 30% in the HIV incidence rate between surveys. DISCUSSION: The results from HIPSS will provide critical data regarding HIV prevalence and incidence in this community and will establish whether HIV prevention and treatment efforts in a "real world", non-trial setting have an impact on HIV incidence at a population level. Importantly, the study design and methods will inform future methods for HIV surveillance.

Indexed as

Family CharacteristicsHIV-1Residence CharacteristicsAdolescentAdultAnti-HIV AgentsCD4 Lymphocyte CountCross-Sectional StudiesFemaleHIV InfectionsHumansIncidenceLongitudinal StudiesMaleMiddle AgedPopulation SurveillanceAnti-HIV Agents

Identifiers

PMID26588902
PMCPMC4654918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.